Xeris Biopharma (NASDAQ:XERS) traded higher on Thursday after Oppenheimer launched its coverage with an Outperform rating and a $5 per share target, citing its drug formulation technologies, XeriSol ...
Source LinkXeris Biopharma (NASDAQ:XERS) traded higher on Thursday after Oppenheimer launched its coverage with an Outperform rating and a $5 per share target, citing its drug formulation technologies, XeriSol ...
Source Link
Comments